aTyr Pharma Inc (LIFE.OQ)
25 May 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|63||2005||Non-Executive Independent Chairman of the Board|
|57||2015||Chief Executive Officer, Director|
|40||2017||Senior Vice President - Finance|
|58||2016||Senior Vice President - Research|
|58||2016||Senior Vice President, Product Programs and Planning|
- BRIEF-aTyr Pharma announces qtrly net loss per share, basic and diluted $0.56
- BRIEF-Atyr Pharma announces promising top-line results from Resolaris
- BRIEF-aTyr Pharma appoints of Timothy P. Coughlin to its board
- BRIEF-aTyr Pharma qtrly net loss per share attributable to common stockholders $0.53
- BRIEF-Atyr Pharma reports issuance of U.S. patent that extends patent protection of physiocrines